Castle Biosciences (CSTL) Non Operating Investment Income (2025 - 2026)
Castle Biosciences (CSTL) posted Non Operating Investment Income of -$630000.0 for Q2 2026, down 131.16% sequentially from $2.0 million in Q1 2026, and down 153.16% YoY from $1.2 million in Q2 2025.
Castle Biosciences (CSTL) Non Operating Investment Income (2025 - 2026) Analysis & Trends
Castle Biosciences has reported Non Operating Investment Income for 2 years, with the latest figure at -$630000.0 in Q2 2026.
- Quarterly Non Operating Investment Income fell 153.16% year-over-year to -$630000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.2 million (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, up 164.14% from the prior year.
- Non Operating Investment Income declined to -$630000.0 in Q2 2026 per CSTL's latest filing, from $2.0 million in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $2.0 million in Q1 2026 and troughed at -$1.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Op. Investment Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.77 Bn | 209.71 Bn | 8.34 Bn | - |
| 2 | Danaher | 139.78 Bn | 135.43 Bn | 3.61 Bn | - |
| 3 | Idexx Laboratories | 46.04 Bn | 45.85 Bn | 779.09 Mn | - |
| 4 | Agilent Technologies | 39.68 Bn | 37.88 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 39.34 Bn | 37.26 Bn | 1.44 Bn | - |
| 6 | Natera | 38.75 Bn | 37.65 Bn | 696.04 Mn | - |
| 7 | Illumina | 29.90 Bn | 28.73 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.58 Bn | 28.53 Bn | 650.22 Mn | - |
| 9 | Quest Diagnostics | 26.18 Bn | 25.55 Bn | 1.03 Bn | - |
| 10 | Castle Biosciences | 943.28 Mn | 676.46 Mn | 79.85 Mn | -630,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -630,000.00 |
| Jun 30, 2026 | -630,000.00 |
| Mar 31, 2026 | 2.02 Mn |
| Mar 31, 2026 | 2.02 Mn |
| Mar 31, 2025 | -1.43 Mn |
| Mar 31, 2025 | -1.43 Mn |